Publications

Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021.

JCO Oncol Pract
Shahzad M, Costa R, Argetsinger S, Ross-Degnan D, Zhang F, Wharam JF, Rosenberg CL, Wagner AK.

Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals

JAMA Network
Robin Forrest, MSc, PhD; Ajay Aggarwal, MD, PhD; Michelle Tregear, MA, PhD
Melanie Wyne, JD; Holly Fernandez Lynch, JD; Anita K. Wagner, PharmD, MPH; Emily Jackson,; Huseyin Naci, MHS, PhD

Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer

Cancer Epidemiol.
Dottino JA, Baumann KE, Esselen KM, Costa R, Argetsinger S, Ross-Degnan D, Wagner AK.

Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer.

Cancer Epidemiol
Dottino JA, Baumann KE, Esselen KM, Costa R, Argetsinger S, Ross-Degnan D, Wagner AK.

Assessment of Oral Anticancer Medicines in Pediatric Patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021.

J Pediatr
Shahzad M, DuBois SG, Costa R, Argetsinger S, Ross-Degnan D, Bourgeois FT, Wagner AK.

Assessment of Oral Anticancer Medicines in Pediatric Patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021

J Pediatr.
Shahzad M, DuBois SG, Costa R, Argetsinger S, Ross-Degnan D, Bourgeois FT, Wagner AK.

Completion and outcomes of postmarketing requirements and commitments issued by the US Food and Drug Administration for new drugs, 2016-24: cross sectional evaluation of postmarketing studies.

BMJ Med
Siebert M, McGonigle R, Gutiérrez-Sacristán A, Naci H, Wagner AK, Bourgeois FT.

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study

PLoS Med.
McGonigle R, Naci H, Siebert M, Ouvina M, Gutiérrez-Sacristán A, Wagner AK, Bourgeois FT.

Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation

BMJ Med.
Naci H, Shahzad M, Murphy P, Zhang Y, Costa R, Ross JS, Wagner AK.

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study.

PLoS Med
McGonigle R, Naci H, Siebert M, Ouvina M, Gutiérrez-Sacristán A, Wagner AK, Bourgeois FT.

Threats of Weather Disasters for Drug Manufacturing Facilities in the US.

JAMA
Shahzad M, Nogueira LM, Wagner A.

Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study

BMJ Evidence-Based Medicine
Yichen Zhang, Huangqianyu Li, Jinyu Chen, Huseyin Naci, Anita K Wagner, Luwen Shi, Xiaodong Guan

Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years: A Natural Experiment for Translation in Diabetes (NEXT-D) Study.

Med Care
Ross-Degnan D, Argetsinger S, Lu CY, Wagner A, Lakoma M, Zhang F, Wharam JF.

Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

JAMA
Cherla A, Wagner AK, Wouters OJ, Woloshin S, Davis C, Mossialos E, Naci H

Threats of Weather Disasters for Drug Manufacturing Facilities in the US

JAMA
Shahzad M, Nogueira LM, Wagner A.

Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis

The Lancet. Oncology
Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner AK, Ross JS, Guan X

More employers offer preventive drug lists over time.

Am J Manag Care
Wagner AK, Argetsinger S, Lakoma M, Clemenzi J, Zhang F, Wharam JF, Ross-Degnan D.

More employers offer preventive drug lists over time

The American Journal of Managed Care
Wagner AK, Argetsinger S, Lakoma M, Clemenzi J, Zhang F, Wharam JF, Ross-Degnan D

Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years: A Natural Experiment for Translation in Diabetes (NEXT-D) Study

Medical Care
Ross-Degnan D, Argetsinger S, Lu CY, Wagner A, Lakoma M, Zhang F, Wharam JF.

New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22.

Health Aff (Millwood)
Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, Naci H